Recently, Leadsynbio’s microbially fermentation-based β-nicotinamide mononucleotide (NMN) reached another core U.S. market compliance milestone, officially receiving a New Dietary Ingredient (NDI) No Objection Letter from the U.S. FDA, with NDIN No. 1497.
[ Details ]Nov 16,2026
On November 11,Leadsynbio showcased our core products and new product plans at API China 2026, engaging with customers and industry experts to discuss technology frontiers and innovative applications, and to explore pathways for sustainable industrydevelopment.
[ Details ]Nov 16,2026
CPHI Milan 2026, the world's leading pharmaceutical ingredients exhibition, was held in Milan, Italy, from October 6 to 8. Leadsynbio took part, connecting with customers and partners from Europe and around the world to discuss green biomanufacturing, stable supply, and long-term collaboration.
[ Details ]Oct 12,2026
Recently, Leadsynbio completed a RMB 450 million Pre-IPO financing round.
[ Details ]Sep 30,2026
Recently, Leadsynbio’s microbial-fermentation-produced NMN has officially passed the authentication of U.S. Self-GRAS. This signifies that our NMN can be sold and used as a safe and compliant food ingredient in the U.S. market, providing crucial supportfor Leadsynbio’s global expansion.
[ Details ]Sep 03,2026
From August 24 to 26, 2026, Leadsynbio made a strong presence at the 6th World Natural & Health Ingredients Expo (WPE&WHPE 2026), engaging in in-depth exchanges with industry partners and clientson topics ranging from natural health ingredients to broader collaboration opportunities.
[ Details ]Aug 28,2026
Stress, hormonal shifts, and late nights are taking a toll on hair health, especially among the young. Androgenetic alopecia only adds to the challenge. Yet amid the search for solutions, NMN has evolved from a mere clue into an evidence-backed answer.
[ Details ]Aug 12,2026
Leadsynbio was recently featured on Suzhou News. The segment will take you inside our biomanufacturing lab, offering a firsthand look at our development and deployment of synthetic biology.
[ Details ]Aug 11,2026
Recently, theproject in which Leadsynbio participated was awarded the Second Prize of the 2025 State Scientific and Technological Progress Award.
[ Details ]Jul 14,2026
On June 18–19, China Veterinary Drug Conference and Exhibition 2026 was held at the Hefei Binhu International Convention and Exhibition Center. Anhui Liberty Pharmaceutical Co., Ltd., a wholly‑owned subsidiary of Leadsynbio, joined the provincial delegationas a representative of outstanding animal health enterprises from Anhui, engaging with industry peers to explore new dynamics in the sector.
[ Details ]Jun 22,2026
Recently, Leadsynbio’s microbially fermentation-based β-nicotinamide mononucleotide (NMN) reached another core U.S. market compliance milestone, officially receiving a New Dietary Ingredient (NDI) No Objection Letter from the U.S. FDA, with NDIN No. 1497.